Search
Gataparsen
go.drugbank.com/drugs/DB05141InvestigationalLY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. LY2181308 is known to target baculoviral IAP repeat-containing protein 5.
Cretostimogene grenadenorepvec
go.drugbank.com/drugs/DB05148InvestigationalCG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF.
Amilomotide
go.drugbank.com/drugs/DB05150InvestigationalCAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's diseas...
NGX267
go.drugbank.com/drugs/DB05152InvestigationalNGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
SL017
go.drugbank.com/drugs/DB05156ExperimentalSL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
Elafin
go.drugbank.com/drugs/DB05161InvestigationalThe excellent tolerability of Elafin in human subjects was demonstrated in a Phase I clinical single dose escalating study. … Elafin is a human protein that is produced naturally in the skin, lung and breast, protecting the respective tissue from destruction by the immune system.
AT9283
go.drugbank.com/drugs/DB05169InvestigationalAT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.
E-2012
go.drugbank.com/drugs/DB05171ExperimentalE-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
MLN0415
go.drugbank.com/drugs/DB05183ExperimentalMLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. … In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.
XL228
go.drugbank.com/drugs/DB05184InvestigationalXL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation